Condition: Advanced Solid Tumor · Sponsor: Codiak BioSciences
This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent, injectable solid tumors, whose disease has progressed despite receiving standard of care treatment. CDK 002 will be administered intratumorally (IT). Part A will enroll subjects with advanced/metastatic, recurrent, injectable solid tumors with emphasis on head and neck squamous cell cancer (HNSCC), triple negative breast cancer (TNBC), anaplastic thyroid carcinoma (ATC) and cutaneous squamous cell carcinoma (cSCC).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Honor Health | Scottsdale, Arizona, United States | — |
| Columbia University/CUMC | New York, New York, United States | — |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
| NEXT Oncology | San Antonio, Texas, United States | — |
| The Beatson West of Scotland Cancer Centre/ Gartnavel General Hospital | Glasgow, United Kingdom | — |
| Oxford University Hospitals NHS Trust | Headington, United Kingdom | — |
| The Royal Marsden Hospital | London, United Kingdom | — |
| The Christie NHS Foundation Trust | Manchester, United Kingdom | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04592484